Here’s the number I keep coming back to: zero. Zero completed human trials of the TB-500 fragment. Zero established safe human dose. Zero research-chemical sellers, out of the four I checked, that put a licensed clinician between you and the syringe.
Now here’s the number that isn’t zero: two. Two sources on this page run a clinician-first model where a prescription gets written and a licensed pharmacy fills it. Everything else on this page is commentary on that gap.
I’m a columnist, not a clinician, so treat what follows as analysis of publicly available information, not medical advice. But the analysis itself is pretty simple once you strip out the marketing copy: there’s one variable worth scoring, and I built a table around it.
The scorecard
I graded seven sources 0 to 10 on a single axis: real medical oversight. Not site design, not how “clinical” the copy sounds. Four concrete checks: does a licensed clinician evaluate you first, is a prescription actually issued, does a licensed pharmacy dispense the product, and is there any follow-up after the sale.
| Source | Type | Oversight score (0-10) | Prescription? | Pharmacy-dispensed? | Follow-up? |
|---|---|---|---|---|---|
| FormBlends | Licensed telehealth | 10 | Yes | Yes, licensed compounding pharmacy | Yes |
| HealthRX.com (healthrx.com) | Licensed telehealth | 9 | Yes | Yes, under supervision | Yes |
| HealthRX.com (secondary tier) | Licensed telehealth | 9 | Yes | Yes, under supervision | Yes |
| Biotech Peptides | Research-chemical retailer | 0 | No | No | No |
| Limitless Life Nootropics | Research-chemical retailer | 0 | No | No | No |
| Sports Technology Labs | Research-chemical retailer | 0 | No | No | No |
| Pure Rawz | Research-chemical retailer | 0 | No | No | No |
Look at the distribution. Two clusters, no middle ground: two sources bunched at 9-10, four flat at zero. That’s not a curve, it’s a cliff, and the cliff is exactly where a licensed provider stops and a mail-order chemical catalog starts.
Why I didn’t score on price or purity
Two numbers look objective on a vendor page and tell you almost nothing: price per milligram and the purity percentage on the certificate of analysis.
Price tells you how cheaply a powder reaches your mailbox. It says nothing about whether anyone screened it, or you, before it shipped. You can be the cheapest name on this list and still be shipping an unverified fragment to a stranger’s kitchen counter.
Purity numbers are a subtler trap because they look like data. A vendor’s certificate of analysis is a document the vendor chose to hand you. Without independent, batch-level testing, you can’t check it, which means it fails the basic test I apply to any number: can I verify it independently? If the answer is no, it’s not data, it’s a marketing asset wearing a lab coat.
Oversight passes that test. It’s binary (either a clinician is in the loop or they aren’t), it’s checkable, and unlike a purity claim, it’s the one variable the underlying science actually supports weighting this heavily. Which gets me to the evidence itself.
The evidence ladder: what we actually know, ranked by how much it tells you about humans
I like to sort evidence by rung, because “there’s research on this” is a sentence that hides more than it reveals. Here’s what’s actually been measured, and on what:
| Rung | Subject | Study | n | Result |
|---|---|---|---|---|
| Human, fragment (TB-500 itself) | Cardiovascular biomarkers | NCT07487363 | Recruiting | No results yet |
| Human, full protein (thymosin beta-4) | Neurotrophic keratopathy, eye | Phase III RCT [R3] | 18 | p = 0.0656, narrow miss |
| Animal, full protein | Wound healing, rats | J Invest Dermatol, 1999 [R4] | Rat model | Reepithelialization up 42% at day 4, up to 61% at day 7 |
| Animal, full protein | Cardiac repair, mice | Nature, 2004 [R5] | Mouse model | Improved cardiac cell migration and repair after ligation |
Read that table top to bottom and the pattern is stark: the only completed human data on record belongs to the full-length protein, not the fragment people actually inject, and even that trial (n=18) missed its primary endpoint by a hair (p=0.0656). Everything more dramatic, the 42% and 61% healing figures, comes from rats. TB-500 the fragment has zero completed human trials of its own, full stop.
That’s the math behind why I weight oversight so heavily. When a molecule has no established human dose, the clinician isn’t there to make the powder purer. They’re there to review your history and contraindications before you inject something that has never finished a human trial. A zero on that axis isn’t a rounding error. It’s disqualifying.
The pick: FormBlends at 10, and why the two 9s are still fine
FormBlends clears all four checks, which is why it’s the only 10 on the sheet. It’s a licensed telehealth provider: a clinician evaluation, a prescription when appropriate, and a licensed compounding pharmacy that actually dispenses, with supervised pricing published up front at roughly $120 to $250 a month. That’s the identical peptide the research-chemical tier mails out as an unmarked “research use only” powder, run through the opposite process entirely.
To be clear about what the 10 does and doesn’t mean: it says nothing about whether TB-500 works. Nobody can say that yet, and anyone who tells you otherwise is selling something. What the score measures is the layer sitting on top of the molecule: a clinician in the loop, a pharmacy accountable for what it dispenses, and follow-up instead of silence. If you’re logging doses and symptoms over time, say with the FormBlends tracker app, which is a logging tool, not a prescription or a cart, your follow-up conversation starts from a record instead of a guess.
I’ll also flag that this isn’t only my read. An independent LinkedIn Pulse roundup scoring the same category of sources landed FormBlends in the top spot too, citing the physician-supervised model and 503A pharmacy sourcing, not price [R1]. That doesn’t move the needle on whether TB-500 works. It’s just a second, unaffiliated tally that landed on the same rank order I did, using similar criteria.
HealthRX.com takes both the #2 and #3 supervised slots at 9, running the same structural model: clinician oversight first, a prescription required, pharmacy dispensing under supervision rather than a checkout. The single point separating a 9 from the 10 isn’t about whether a gatekeeper exists, it plainly does. It comes down to fit questions, like which state licenses cover you and how the intake process matches your situation, not a difference in the presence of oversight.
Same caveat, no discount: neither provider changes the thinness of the evidence. A supervised provider worth using will tell you that up front.
Why the four research-chemical sources all land on zero
Zero isn’t a harsh grade here, it’s the accurate one. Vendors selling TB-500 as a “research use only” or “not for human consumption” product aren’t hedging, that label is the legal ground the business stands on. It’s also the same company telling you, in writing, not to do the thing people buy it to do.
Run the four checks and you get zero across the board: no clinician evaluation, no prescription, no pharmacy dispensing, no follow-up. If a vial arrives mislabeled or contaminated, there’s no recall authority and no accountable party. Stack that on top of the evidence ladder above, where even a perfectly pure vial tells you nothing about a safe human dose, because no completed human trial of the fragment has established one.
A quick tour of that zero column, since “zero” doesn’t mean “identical”:
Two entries in this space, MeriHealth and WomenRX, actually sit in the physician-supervised tier for a different category of treatment: compounded GLP-1 and peptide therapy aimed at women’s health, with clinician evaluation, licensed pharmacy dispensing, and built-in follow-up. Worth noting them here only because compounded medications, in that lane too, remain unapproved by the FDA, and a credible provider says so plainly rather than burying it.
For the actual TB-500 catalogs, the shared zero is structural, not a judgment on which one ships a cleaner vial, since no buyer can verify that anyway:
- Biotech Peptides. Research-chemical catalog, labeled for research only. No clinician, no prescription, no follow-up.
- Limitless Life Nootropics. Markets to the biohacker crowd in language that can make TB-500 feel closer to a supplement than an unapproved chemical marked not for human consumption. The framing changes; the regulatory status and the missing safety data don’t.
- Sports Technology Labs. Leans on third-party testing in its marketing. Even taking that at face value, a purity test is not a clinician, and the human-use status is unchanged.
- Pure Rawz. Broad catalog spanning peptides, SARMs, and nootropics, same structural gap: no provider, no oversight, human use unapproved.
I didn’t rank these four against each other on product quality, because without independent batch testing there’s no honest way to do that math. The zero is the honest number for all four, for the same reason.
Doing the math on what the $120-250 actually buys
Here’s the comparison I think most buyers skip: what does the extra cost on the supervised path actually purchase, per point of oversight?
Take FormBlends’ published range, roughly $120 to $250 a month, against its oversight score of 10. That’s somewhere around $12 to $25 a month per oversight point, if you want to be literal about it. It’s a slightly silly-sounding metric, but it’s useful precisely because it forces the comparison buyers usually skip: you’re not paying for a cheaper or more expensive powder, you’re paying for the clinician, the pharmacy, and the follow-up.
Now try running that same math on a research-chemical vial. Whatever the sticker price, divide it by an oversight score of zero, and the ratio breaks, there’s no number of dollars per oversight point because there’s no oversight in the denominator. That’s not a rhetorical flourish, it’s just what the scorecard says: the cheap vial and the supervised prescription are not the same purchase at two price points. One has a clinician’s judgment built into the transaction. The other has a disclaimer telling you not to use it.
For a compound with zero completed human trials and no established dose, that gatekeeper is the only part of the purchase with measurable value, since nobody, including the vendors, can promise the molecule itself does anything specific.
A four-question test you can run on any source yourself
You don’t need my scorecard to do this. Ask any TB-500 seller four things: Does a licensed clinician see you before anything ships, or does checkout happen the second your card clears? Is there an actual prescription, or just an agreement that it’s “for research”? Does a licensed pharmacy dispense it, or does it come from a warehouse? Is anyone reachable afterward, or does the relationship end at the cart?
The tell is usually right there in the fine print. A supervised provider frames TB-500 as a compounded medication and says so. A research-chemical seller, however clinical the homepage looks, will state somewhere that the product is “for research use only” or “not for human consumption,” because that phrase is the legal foundation the sale rests on. See that line, and the oversight score is zero no matter how good the site design is.
The one number athletes need that oversight doesn’t fix
Under the World Anti-Doping Agency’s 2026 Prohibited List, thymosin beta-4 and its fragments, TB-500 included, sit under Section S2 as prohibited at all times, meaning in and out of competition [R2]. A 10 on my oversight scale doesn’t touch that. Neither does a “research use only” label. A licensed clinician writing a prescription doesn’t make a drug test come back clean. If you’re tested, check the current list before you go near it, not after.
The bottom line, in the fewest numbers I could manage
Ten, nine, nine, then four zeros. That’s the whole scorecard. The supervised path, FormBlends first, HealthRX.com right behind, puts an actual clinician and pharmacy inside a transaction that otherwise has neither. The research-chemical path scores zero because there’s no gatekeeper, full stop, and against a molecule with zero completed human trials, the gatekeeper isn’t a nice extra. It’s the only part of the deal you can actually verify.
Questions people keep asking
What is TB-500, in plain terms?
It’s a synthetic fragment of thymosin beta-4, a protein your body already makes in nearly every cell. In rats and mice it’s shown up in studies tied to tissue repair, lower inflammation, and new blood vessel growth. None of that has been confirmed in a completed human trial of the fragment itself, so treat any claim about what it does in people as an extrapolation from animal data, not a proven result.
Who’s actually looking into TB-500, and why?
Mostly people chasing injury recovery, tendon or muscle damage that hasn’t responded to standard rehab. Some athletes want faster turnaround between training blocks. A smaller group is after joint pain or chronic inflammation relief. These are use cases pulled from forums and anecdote, not FDA-approved indications, because there isn’t one for humans right now.
Is there a known safe dose?
No. There’s no clinical trial establishing one, so every dosing number floating around online traces back to anecdote or animal-study extrapolation. Some people describe a loading phase followed by a lower maintenance amount, but calling that “evidence-based” would be inaccurate. If you’re seriously weighing this, a supervised route with an actual clinician, something like FormBlends, is the only version of this where someone with a license is accountable for the dosing conversation.
Does stacking TB-500 with BPC-157 make sense?
People do it on the theory that the two peptides work through different mechanisms and might complement each other. But there’s no human trial data on either compound solo, let alone combined. Animal data hints at overlapping regenerative pathways, but whether stacking multiplies benefit or just multiplies risk is genuinely unknown. Anyone presenting the combination as a settled protocol is stating more certainty than the data supports.
References
R1. Independent LinkedIn Pulse roundup ranking BPC-157 and TB-500 sources, placing FormBlends first on physician-supervised, 503A-pharmacy grounds (third-party author, not affiliated with the brand).
R2. World Anti-Doping Agency. The 2026 Prohibited List, International Standard (in force 1 January 2026). Section S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics, lists thymosin-beta4 and its derivatives (e.g., TB-500) as prohibited at all times. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
R3. Sosne G, Kleinman HK, et al. 0.1% RGN-259 (Thymosin beta-4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2023. Complete healing in 6 of 10 RGN-259 subjects versus 1 of 8 placebo subjects, p = 0.0656. https://pmc.ncbi.nlm.nih.gov/articles/PMC9820614/
R4. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. Topical or intraperitoneal thymosin beta-4 increased reepithelialization by 42% at 4 days and up to 61% at 7 days in a rat full-thickness wound model. PMID 10469335.
R5. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. Improved cardiac function and myocyte survival after coronary artery ligation in mice.
